<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33177491</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The mechanism of m<sup>6</sup>A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene.</ArticleTitle>
        <Pagination>
          <StartPage>969</StartPage>
          <MedlinePgn>969</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">969</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-03148-8</ELocationID>
        <Abstract>
          <AbstractText>N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification can alter gene expression by regulating RNA splicing, stability, translocation, and translation. Emerging evidence shows that m<sup>6</sup>A modification plays an important role in cancer development and progression, including cell proliferation, migration and invasion, cell apoptosis, autophagy, and drug resistance. Until now, the role of m<sup>6</sup>A modification mediated autophagy in cancer drug resistance is still unclear. In this study, we found that m<sup>6</sup>A methyltransferase METTL3-mediated autophagy played an important role in reversing gefitinib resistance by β-elemene in non-small cell lung cancer (NSCLC) cells. Mechanistically, in vitro and in vivo studies indicated that β-elemene could reverse gefitinib resistance in NSCLC cells by inhibiting cell autophagy process in a manner of chloroquine. β-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and LC3B-II. Moreover, both β-elemene and gefitinib decreased the level of m<sup>6</sup>A methylation of gefitinib resistance cells. METTL3 was higher expressed in lung adenocarcinoma tissues than that of paired normal tissues, and was involved in the gefitinib resistance of NSCLC cells. Furthermore, METTL3 positively regulated autophagy by increasing the critical genes of autophagy pathway such as ATG5 and ATG7. In conclusion, our study unveiled the mechanism of METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by β-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Shuiping</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Qiujie</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guohua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhuo</LastName>
            <ForeName>Lvjia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Xuemeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Mingming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiaying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jianjun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory medicine, the Affiliated Hospital of Hangzhou Normal University, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 310015, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Qun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory medicine, the Affiliated Hospital of Hangzhou Normal University, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 310015, China. hzlvqun@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sui</LastName>
            <ForeName>Xinbing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China. hzzju@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China. hzzju@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China. xbs@hznu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China. xbs@hznu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C445979">beta-elemene</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.-</RegistryNumber>
          <NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.62</RegistryNumber>
          <NameOfSubstance UI="C468275">METTL3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008780" MajorTopicYN="N">Methyltransferases</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012717" MajorTopicYN="N">Sesquiterpenes</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33177491</ArticleId>
        <ArticleId IdType="pmc">PMC7658972</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-020-03148-8</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-020-03148-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Becker N, et al.  Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int. J. Cancer. 2020;146:1503–1513. doi: 10.1002/ijc.32486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32486</ArticleId>
            <ArticleId IdType="pubmed">31162856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Zhang X, Yang C, Xu S. MicroRNA-198-5p inhibits the migration and invasion of non-small lung cancer cells by targeting fucosyltransferase 8. Clin. Exp. Pharmacol. Physiol. 2019;46:955–967. doi: 10.1111/1440-1681.13154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1440-1681.13154</ArticleId>
            <ArticleId IdType="pubmed">31381176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stumpf C, et al.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer. J. Cancer Res. Clin. Oncol. 2018;144:1921–1932. doi: 10.1007/s00432-018-2722-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-018-2722-5</ArticleId>
            <ArticleId IdType="pubmed">30076481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoneda K, et al.  Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br. J. Cancer. 2019;121:490–496. doi: 10.1038/s41416-019-0541-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-019-0541-3</ArticleId>
            <ArticleId IdType="pmc">PMC6738061</ArticleId>
            <ArticleId IdType="pubmed">31388183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CH, et al.  Combination of whole-brain radiotherapy with epidermal growth factor receptor tyrosine kinase inhibitors improves overall survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Cancers. 2019;11:8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721307</ArticleId>
            <ArticleId IdType="pubmed">31370314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao C, Wang Q, Liu Y. Lung cancer combination therapy: doxorubicin and beta-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des. Devel. Ther. 2019;13:1087–1098. doi: 10.2147/DDDT.S198003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DDDT.S198003</ArticleId>
            <ArticleId IdType="pmc">PMC6498957</ArticleId>
            <ArticleId IdType="pubmed">31118562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong M, et al.  Beta-elemene inhibits cell proliferation by regulating the expression and activity of topoisomerases I and IIalpha in human hepatocarcinoma HepG-2 cells. Biomed. Res. Int. 2015;2015:153987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4499621</ArticleId>
            <ArticleId IdType="pubmed">26221582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan Y, et al.  Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation. J. Cell Mol. Med. 2019;23:6846–6858. doi: 10.1111/jcmm.14568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.14568</ArticleId>
            <ArticleId IdType="pmc">PMC6787513</ArticleId>
            <ArticleId IdType="pubmed">31343107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao C, et al.  Beta-elemene reverses the drug resistance of A549/DDP lung cancer cells by activating intracellular redox system, decreasing mitochondrial membrane potential and P-glycoprotein expression, and inducing apoptosis. Thorac. Cancer. 2014;5:304–312. doi: 10.1111/1759-7714.12093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1759-7714.12093</ArticleId>
            <ArticleId IdType="pmc">PMC4704358</ArticleId>
            <ArticleId IdType="pubmed">26767017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao YF, et al.  P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. Biomed. Pharmacother. 2011;65:151–156. doi: 10.1016/j.biopha.2011.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2011.02.009</ArticleId>
            <ArticleId IdType="pubmed">21616632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mu L, et al.  Beta-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway. Int. J. Oncol. 2016;49:1427–1436. doi: 10.3892/ijo.2016.3626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2016.3626</ArticleId>
            <ArticleId IdType="pubmed">27498706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parousis A, et al.  Contractile activity attenuates autophagy suppression and reverses mitochondrial defects in skeletal muscle cells. Autophagy. 2018;14:1886–1897. doi: 10.1080/15548627.2018.1491488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2018.1491488</ArticleId>
            <ArticleId IdType="pmc">PMC6152519</ArticleId>
            <ArticleId IdType="pubmed">30078345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, et al.  The role of NLRP3-CASP1 in inflammasome-mediated neuroinflammation and autophagy dysfunction in manganese-induced, hippocampal-dependent impairment of learning and memory ability. Autophagy. 2017;13:914–927. doi: 10.1080/15548627.2017.1293766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2017.1293766</ArticleId>
            <ArticleId IdType="pmc">PMC5446056</ArticleId>
            <ArticleId IdType="pubmed">28318352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai Y, Grant S. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy. 2015;11:416–418. doi: 10.1080/15548627.2014.998892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2014.998892</ArticleId>
            <ArticleId IdType="pmc">PMC4502657</ArticleId>
            <ArticleId IdType="pubmed">25700997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai CH, et al.  YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction. Biochim. Biophys. Acta Mol. Basis Dis. 2018;1864:3786–3798. doi: 10.1016/j.bbadis.2018.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2018.10.015</ArticleId>
            <ArticleId IdType="pubmed">30315932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee TG, Jeong EH, Kim SY, Kim HR, Kim CH. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Int. J. Cancer. 2015;136:2717–2729. doi: 10.1002/ijc.29320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29320</ArticleId>
            <ArticleId IdType="pubmed">25382705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, et al.  Roles of RNA methylation by means of N(6)-methyladenosine (m(6)A) in human cancers. Cancer Lett. 2017;408:112–120. doi: 10.1016/j.canlet.2017.08.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2017.08.030</ArticleId>
            <ArticleId IdType="pubmed">28867248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, et al.  The role of mRNA m(6)A methylation in the nervous system. Cell Biosci. 2019;9:66. doi: 10.1186/s13578-019-0330-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13578-019-0330-y</ArticleId>
            <ArticleId IdType="pmc">PMC6701067</ArticleId>
            <ArticleId IdType="pubmed">31452869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min KW, et al.  Profiling of m6A RNA modifications identified an age-associated regulation of AGO2 mRNA stability. Aging Cell. 2018;17:e12753. doi: 10.1111/acel.12753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/acel.12753</ArticleId>
            <ArticleId IdType="pmc">PMC5946072</ArticleId>
            <ArticleId IdType="pubmed">29573145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, et al.  The interplay between m6A RNA methylation and noncoding RNA in cancer. J. Hematol. Oncol. 2019;12:121. doi: 10.1186/s13045-019-0805-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-019-0805-7</ArticleId>
            <ArticleId IdType="pmc">PMC6874823</ArticleId>
            <ArticleId IdType="pubmed">31757221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, et al.  Dynamic m(6)A mRNA methylation reveals the role of METTL3-m(6)A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene. 2019;38:4755–4772. doi: 10.1038/s41388-019-0755-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-019-0755-0</ArticleId>
            <ArticleId IdType="pmc">PMC6756049</ArticleId>
            <ArticleId IdType="pubmed">30796352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, et al.  Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med. 2019;8:4766–4781. doi: 10.1002/cam4.2360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.2360</ArticleId>
            <ArticleId IdType="pmc">PMC6712480</ArticleId>
            <ArticleId IdType="pubmed">31243897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452–460. doi: 10.4161/auto.4451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/auto.4451</ArticleId>
            <ArticleId IdType="pubmed">17534139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, et al.  Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12:1–222. doi: 10.1080/15548627.2015.1100356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2015.1100356</ArticleId>
            <ArticleId IdType="pmc">PMC4835977</ArticleId>
            <ArticleId IdType="pubmed">26799652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer. Signal Transduct. Target Ther. 2019;4:25. doi: 10.1038/s41392-019-0059-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-019-0059-4</ArticleId>
            <ArticleId IdType="pmc">PMC6799834</ArticleId>
            <ArticleId IdType="pubmed">31637005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, et al.  The emerging molecular mechanism of m(6)A modulators in tumorigenesis and cancer progression. Biomed. Pharmacother. 2020;127:110098. doi: 10.1016/j.biopha.2020.110098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2020.110098</ArticleId>
            <ArticleId IdType="pubmed">32299028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, et al.  Beta-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 2011;11:183. doi: 10.1186/1471-2407-11-183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-11-183</ArticleId>
            <ArticleId IdType="pmc">PMC3115914</ArticleId>
            <ArticleId IdType="pubmed">21595977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding XF, Shen M, Xu LY, Dong JH, Chen G. 13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-beta-elemene, a novel beta-elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast cancer cells. Oncol. Lett. 2013;5:1554–1558. doi: 10.3892/ol.2013.1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2013.1213</ArticleId>
            <ArticleId IdType="pmc">PMC3678516</ArticleId>
            <ArticleId IdType="pubmed">23761818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed. Pharmacother. 2019;112:108613. doi: 10.1016/j.biopha.2019.108613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2019.108613</ArticleId>
            <ArticleId IdType="pubmed">30784918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, et al.  m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 2018;20:1074–1083. doi: 10.1038/s41556-018-0174-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0174-4</ArticleId>
            <ArticleId IdType="pmc">PMC6245953</ArticleId>
            <ArticleId IdType="pubmed">30154548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, et al.  The roles and mechanisms of YTH domain-containing proteins in cancer development and progression. Am. J. Cancer Res. 2020;10:1068–1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7191095</ArticleId>
            <ArticleId IdType="pubmed">32368386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, et al.  METTL3 plays multiple functions in biological processes. Am. J. Cancer Res. 2020;10:1631–1646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7339281</ArticleId>
            <ArticleId IdType="pubmed">32642280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, et al.  m(6)A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2020;2020:1–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31983283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Z, et al.  RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181. doi: 10.15252/embj.2019103181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.2019103181</ArticleId>
            <ArticleId IdType="pmc">PMC7298296</ArticleId>
            <ArticleId IdType="pubmed">32368828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, et al.  m(6)A mRNA methylation controls autophagy and adipogenesis by targeting Atg5 and Atg7. Autophagy. 2020;16:1221–1235. doi: 10.1080/15548627.2019.1659617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2019.1659617</ArticleId>
            <ArticleId IdType="pmc">PMC7469583</ArticleId>
            <ArticleId IdType="pubmed">31451060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song H, et al.  METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy. 2019;15:1419–1437. doi: 10.1080/15548627.2019.1586246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2019.1586246</ArticleId>
            <ArticleId IdType="pmc">PMC6613905</ArticleId>
            <ArticleId IdType="pubmed">30870073</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
